The overall ratings of five Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell"). More
-
-
Sponsored By:
-
Sponsored By:
DNDN
Recent Articles
Upgraded Biotech Flashes Short-Term Buy Signal
Dendreon's 20-day moving average recently crossed up through its 200-day moving average. Get the target for DNDN. More
Surprise! Dendreon Doesn’t Stink Anymore
It took three years, but this biotech may be quietly finding its footing as its innovative Provenge prostate-cancer fighter gains credibility. More
S&P Hits Five-Year High — Thursday’s IP Market Recap
Positive earnings news, big corporate headlines and solid China exports helped move markets north and launched the S&P to five-year highs. More
Stocks Pop to Open 2013 — Wednesday’s IP Market Recap
A deal averting the fiscal cliff sent stocks on a large, broad rally, including a 30-for-30 day for the Dow Jones Industrial Average More
Not Enough Spark From ‘Merger Monday’ — Monday’s IP Market Recap
Wall Street saw three big deals in the mergers & acquisition world Monday, but the markets mostly shrugged with a flat performance. More
Nothing Left to Do but Vote — Monday’s IP Market Recap
Stocks traded slightly higher on the day, led mostly by a rise in Apple, though many investors shied off big moves before tomorrow's presidential election. More
